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Background: The World Health Organization recommends benzylpenicillin and gentamicin as 
antimicrobial treatment of infants with sepsis in low income settings (LICs), and ceftriaxone or 
cefotaxime as an alternative. In a meta-analysis from 13 LICs, Staphylococcus aureus, Klebsiella 
spp. and E.coli accounted for 55% of infants with sepsis. In a review of bacterial meningitis, 
resistance to third generation cephalosporins was >50% of all isolates, and 44% of Gram-
negative isolates were gentamicin resistant. However, ceftriaxone may cause neonatal jaundice 
and gentamicin may cause deafness. Therefore, we compared parenteral benzylpenicillin plus 
gentamicin to ceftriaxone as first line treatment, assessing outcome and adverse events.  
Methods This was an open randomized trial carried out in the Queen Elizabeth Central Hospital, 
Blantyre, Malawi from 2010 to 2013. Infants < 60 days of age with possible severe sepsis 
received either benzylpenicillin and gentamicin or ceftriaxone. Adverse events and outcomes 
were recorded until 6 months post discharge.  
Results: 348 infants were included in analyses. Outcome in the benzylpenicillin and gentamicin 
or ceftriaxone groups was similar; deaths were 13.7% and 16.5% and sequelae 14.5% and 11.2% 
respectively. More infants in the penicillin/gentamicin group required phototherapy: 15% v 5%, 
p=0.03. Thirteen (6%) survivors had bilateral hearing loss. There was no difference between the 
treatment groups. By 6 months post discharge 11 more infants had died and 17 more children 
were found to have sequelae. 
 Conclusions Ceftriaxone and gentamicin are safe for infants in our setting.  Infants should 
receive long term follow up as many poor outcomes occurred after hospital discharge. 
 
Abstract
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Introduction 
In an open, randomized trial of Malawian infants <60 days of age with possible severe bacterial 
infection, we compared parenteral benzylpenicillin plus gentamicin to ceftriaxone as first line 
treatment, assessing outcome and adverse events.  
Background 
Clinically suspected possible severe bacterial infections (pSBIs) are common in low-income 
settings, especially in the first month of life when mortality and morbidity are high.1 Early and 
appropriate therapy are critical to a good outcome. Antimicrobial therapy is guided by World 
Health Organisation (WHO) recommendations: first line therapy with parenteral benzylpenicillin 
and gentamicin; second line treatment with cefotaxime or ceftriaxone.2 Gentamicin has a 
potential for toxicity, especially hearing loss, but methods of monitoring blood concentrations of 
the drug are rarely available. There are no studies comparing the two regimens for efficacy, 
adverse events and outcome. Possible severe bacterial infection includes severe pneumonia, 
sepsis and meningitis. The WHO Young Infants sepsis study group reported that in a multicenter 
study in low income countries (LIC) in Asia and Africa, the three most common causes of pSBI 
found were Gram negative enteric bacteria, Group B Streptococcus (GBS) and Streptococcus 
pneumoniae.3 In a meta-analysis of reports from 13 low income settings, Staphylococcus aureus, 
Klebsiella spp. and E.coli accounted for 55% (39-70%) of culture positive sepsis in all infants;4 
findings confirmed in a review of 21 studies, published after 2000, of neonatal invasive 
bacteremia in low income settings, 10 of which were in sub Saharan settings.5 In a six-country 
review of bacterial meningitis, resistance to second and third generation cephalosporins was 
present in >50% of all isolates, and 44% of Gram-negative isolates were gentamicin-resistant.6  
Manuscript
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 Early onset sepsis (<7 days) is often associated with risk factors in the mother and /or 
delivery and the causative agents are GBS, S. aureus and Gram negative bacteria such as E. coli. 
Late onset infections (7-60 days) are commonly caused by bacteria such as S. pneumoniae, S. 
aureus, Klebsiella pneumoniae and also GBS.2   
In high-income settings, first line antimicrobial treatment is usually benzylpenicillin or 
ampicillin and gentamicin for non-meningitis cases, and cefotaxime with ampicillin for 
meningitis or as second line therapy. The ampicillin is to cover Listeria monocytogenes 
infections.7 Ceftriaxone has been avoided in infants because of perceived safety issues, 
especially in infants who are jaundiced or hypoalbuminaemic,8 because ceftriaxone can cause 
biliary sludging, although this is reversed when treatment ceases and has no persisting sequelae.8-
11  Ceftriaxone can form ceftriaxone-calcium complexes if given within 48 hours of a calcium-
containing intravenous (IV) infusion. These complexes precipitate in IV fluid lines, the lungs and 
the kidneys, sometimes with fatal results.12-14 Some national guidelines advise against using 
ceftriaxone in premature babies until they attain the gestational age of 41 weeks.15 Ceftriaxone is 
still the drug of choice in neonatal gonorrheal ophthalmitis.16  
Except in inflamed meninges, gentamicin has poor CNS penetration, achieves rather poor CSF 
levels and does not penetrate well into cells. The therapeutic range is narrow and gentamicin may 
control but fail to eradicate Gram negative infections.17 In Blantyre Listeria monocytogenes is 
exceptionally rare. This may be because a typical Malawian diet does not include unpasteurized 
dairy products or salads. Surrounding countries such as Kenya, South Africa and Zimbabwe 
report similar causes of pSBI as Malawi.18-20  
Cephalosporins are bactericidal antibiotics and although CNS penetration is modest, higher doses 
safely achieve therapeutic CSF drug levels. In Malawi benzylpenicillin is appropriate for GBS 
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infections and for most S. pneumoniae infections.21,22 Klebsiella pneumoniae and, many other 
Gram negative bacteria are increasingly resistant to gentamicin.23,24 
The recommended WHO first line therapy may be inadequate empirical therapy where Gram 
negative bacteria account for half or more of all cases of SBI in infants <2 months of age.  For 
this reason, we compared benzylpenicillin and gentamicin to ceftriaxone as first line treatment 
for pSBI in infants, and monitored for safety, especially jaundice, during therapy.  
Methods 
This was an open randomized trial carried out in the pediatric department of the Queen Elizabeth 
Central Hospital (QECH) in Blantyre, Malawi from March 2010 to February 2013. QECH is an 
1100-bedded public government hospital; it is also the main teaching hospital of the Malawi 
medical school. It serves as the referral hospital for the southern half of the country and also as 
the district hospital for Blantyre. The children’s department admits 28,000 children a year and 
about 80,000 children are seen annually in the emergency unit.    
Inclusion criteria 
Children ≤ 2 months of age in whom there was clinical suspicion of severe sepsis, pneumonia or 
meningitis were eligible for inclusion. Following WHO guidelines, pSBI (including severe 
pneumonia, sepsis and BM) was suspected in the presence of convulsions, bulging fontanelle, 
lethargy, coma, poor feeding, irritability, apneic episodes or abnormal cry.25 In infants <7 days 
old an extended diagnostic algorithm included fever, agitation, no spontaneous movement, 
cyanosis, slow capillary refill (<3 secs) and lower chest wall in-drawing.  
Enrolment took place after the guardian was fully informed and written consent was given. We 
recorded demographic, clinical and laboratory findings, including details about the pregnancy 
and the delivery. 
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Exclusion criteria 
Infants not to be enrolled were: those with clinical severe jaundice (yellow discoloration of the 
skin extending to the lower limbs); children with known hypersensitivity to any of the three 
antibiotics and those who had been hospitalized for >72 hours, to avoid enrolling nosocomial 
infections. Children with previous neurological abnormalities such as hydrocephalus and neural 
tube defects were not enrolled. Excluded patients received standard treatment of benzylpenicillin 
and gentamicin. 
Endpoints 
The primary endpoints were differences in outcome and occurrence of jaundice between the two 
treatment groups. 
Randomization  
Randomization was by computer-generated numbers in blocks of ten. Treatment allocations were 
sealed in consecutively numbered opaque envelopes and opened in numerical order by the 
recruiting clinician at enrolment. Allocation was to either to benzylpenicillin 50,000 iu/kg 8 
hourly IV (100,000 iu 8 hourly IV for BM) and daily gentamicin 6 mg/kg IV (standard smaller 
doses for low birth weight infants and very premature babies) or ceftriaxone IV 50 -100 mg/kg 
od (depending on age) for 5-14 days. 
Samples on admission.  
Laboratory investigations were carried out at the Malawi-Liverpool-Wellcome Trust Clinical 
Research Programme Laboratories which are externally quality controlled. A blood sample was 
taken for a full blood count, culture, electrolytes, glucose and an HIV antibody test 
(Determine®). All infants testing positive by HIV antibody test had a blood sample tested by 
PCR to identify active HIV infection.  
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Cerebral spinal fluid (CSF) was taken for biochemistry, microscopy and culture. A positive CSF 
was one in which a culture was positive or the white cell count was >50 cells/ul with neutrophils 
forming the greater proportion of the cells.   
Clinical monitoring and care 
All infants were monitored by study nurses every 2–4 hours and seen at least twice daily by the 
study team. Most infants had hearing tests and when clinically appropriate an ultrasound scan of 
the head. Bilirubin levels were measured twice daily with a transcutaneous bilirubinometer 
(Konica Minolta Drager Air Shields JM 103). MRIs were carried out when their findings might 
benefit the child. 
We provided supportive care according to unit protocols. Calcium is not added to any infusions 
and serum gentamicin levels are not available. 
If the infant deteriorated despite the treatment given, and after discussion with the principal 
investigator, an appropriate antibiotic could be added to the treatment schedule or a switch made 
to the antibiotic(s) in the other study arm.  If the CSF or blood culture report showed that a child 
was receiving inappropriate antimicrobial therapy for the bacteria grown, the treatment was 
changed for a more suitable antibiotic.  
Follow-up 
 Follow-up was at one and six months after hospital discharge when neurological and hearing 
assessments were done. Age-appropriate hearing tests were carried out by trained nurses using 
oto-evoked potentials (Echocheck) and distraction tests. The neurological assessment was made 
by a trained research clinician. 
Sample size 
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To detect a 40% lower case fatality rate in the ceftriaxone group than in the benzylpenicillin and 
gentamicin group, (ie to reduce the overall case fatality rate of meningitis from 50% to 30%) 
with a confidence of 90% and power of 80% required 107 infants in each arm (total = 214). To 
detect a difference in jaundice development in the ceftriaxone group of 18% compared to 8% in 
the penicillin and gentamicin group, the sample size needed with a confidence of 90% and power 
of 80% was 158 in each arm, (total = 316).  To allow for mortality (much of it early) and loss to 
follow up, an extra 10% were to be recruited; i.e. 174 to each group: 348 in total. 
Statistical Analysis 
Statistical analysis was per protocol, done using Stata version 14.0 StataCorp Texas 77845 
USA. The difference in means of normally distributed variables was performed using an 
independent samples t-test. Chi-square tests were used to assess relationship between categorical 
variables. Univariate logistic regression model was used to assess factors associated with poor 
outcome to obtain unadjusted odds ratios. Multivariate logistic regression model was also fitted 
to identify factors that are independently associated with outcome. All statistical tests were 2 
tailed. Statistical significance was declared at a value of <0.05. The 95% confidence intervals 
for the odds ratios were obtained and reported. 
Adverse events 
 Severe adverse events were reported to a data safety management board (DSMB) through the 
clinical monitor within 48 hours of their occurrence. The main safety endpoint for ceftriaxone 
was a transcutaneous bilirubin level at which phototherapy would be instituted. This level 
depended on gestational and postnatal age according to departmental bilirubin level graphs (see 
tables, Supplemental Digital Content 1 and 2). If levels were reached that required phototherapy, 
it was commenced and 8 hourly transcutaneous bilirubin levels were measured. If bilirubin 
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concentrations decreased or remained stable, further doses of ceftriaxone were given and 
monitoring continued. If bilirubin concentrations increased, no further ceftriaxone was given.   
Serious events included deaths, jaundice levels at or beyond ‘phototherapy’ levels, anemia (Hb 
<6 g/dl) while on therapy and serious adverse drug reactions (rashes, bronchospasm, 
anaphylactic shock). 
Any changes from one antibiotic to another were reported and the reasons for change 
documented. The study was to be stopped if bilirubin levels requiring a change in antibiotic 
therapy were found in 30% more of the children receiving ceftriaxone than of those receiving 
benzylpenicillin and gentamicin. 
 
Ethical considerations 
Benzylpenicillin and gentamicin are widely used to treat neonatal infections despite the 
theoretical complications of renal failure and hearing loss. Ceftriaxone can cause conjugated 
bilirubinaemia and jaundice without permanent sequelae. Ceftriaxone has been used for several 
years in many centers across the region as second line treatment for neonatal infections. 
Nevertheless because of these theoretical complications all infants were monitored closely. 
All guardians gave written consent to be enrolled after being fully informed of the study. 
Permission was granted by the College of Medicine Research and Ethics Committee (COMREC) 
to undertake the study (P2010/819) and the trial was registered with clinicaltrials.gov 
(NCT01247909). 
Results 
From March 2010 to Feb 2013 a total of 351 infants less than 60 days of age were enrolled; one 
parent withdrew consent before signing and two infants were deemed not to require antibiotics. 
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The remaining 348 were included in analyses. (Figure 1) Of these, 161 (46.5%) were given 
gentamicin / benzylpenicillin and 170 received ceftriaxone: 17 received both. Baseline 
characteristics were similar in the two groups, except for prevalence of clinical jaundice (n= 12; 
6.5% in the penicillin v 23; 14% in the ceftriaxone group p=0.02). Table 1 
 Overall inpatient mortality was 12%; (n= 41) and a further 11 died within six months of 
discharge (total mortality n=52;15%). Sequelae were found in 4.6% (n =16) at hospital discharge 
and a further 17 (total =33;12.6%) of 261 survivors at six months after discharge. (Figure 1).  
Causes of death after discharge could not be verified but six (18.7%) had neurological sequelae 
following meningitis, four had significant congenital abnormalities, two HIV positive infants had 
further admissions for probable Pneumocystis jirovecii pneumonia (PJP), four had been admitted 
with severe shock or sepsis and no cause for later death was given.  
Of the 348 patients, 54 (15.5%) did not have a lumbar puncture done, 42 (14.3%) of the 
remaining 294 had positive CSF cultures of which 15 (36.6%) were Group B Streptococcus 
(GBS) and 6 (14.6 %) were Gram negative bacteria such as Acinebacter baumanni, E. coli, 
Klebsiella pneumoniae (Table 2) 
Blood cultures were done in 348 children; 105 (30.1%) were positive; of these 62 (59%) grew 
coagulase negative staphylococci, 9 (8.5%) were Gram negative bacteria, 15 (14.3%) were GBS 
and 11 (10.5%) were Staphylococcus aureus (Table 2).  Overall more children with a positive 
than a negative CSF or blood culture had a poor outcome (25(44%) v 67(33%) p=0.003 and 
21(41%) v 54(30%) p=0.04 respectively (see table, Supplemental Digital Content 3). Coagulase 
negative staphylococci and alpha hemolytic streptococci may have been contaminants but some 
of the infants from whom the samples were taken were very ill. Removing these bacteria from 
analyses made no difference to the findings. The combined outcome by CSF and blood culture 
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results comparing no growth with growth (137 v 122) was also significant (p= 0.017) (see table, 
Supplemental Digital Content 3) 
Outcomes were similar between the two treatment groups; inpatient mortality was 11.2% in both 
the benzylpenicillin and gentamicin and the ceftriaxone arms. (Table 2) At six months post 
discharge, deaths were 13.7% and 16.5% and sequelae in survivors were 14.5% and 11.2%. 
respectively, (Figure 1). 
 On multivariate analysis weight on admission, convulsions, not sucking, an oxygen 
saturation level < 90% and positive blood culture were each associated significantly with 
mortality and sequelae (Table 3).  
More infants in the penicillin/gentamicin group were clinically jaundiced on admission and more 
eventually required phototherapy: n=19; 15% v 7; 5%, p=0.03.  (Table 4). Fifteen infants 
received phototherapy for 1-2 days, 8 for 3-4 days, 6 for 5-6 days and 4 for 7-11 days. Of the 
infants receiving >5 days of phototherapy, two were on ceftriaxone and six were on 
benzylpenicillin; one received both drug treatments.  
Thirteen (6%) of 216 children who were tested had bilateral hearing loss; eight (61.5%) also had 
neurologic sequelae suggesting that the cause was the underlying infection. In four of the 13 
infants with bilateral hearing loss a lumbar puncture was not done as the infants were too sick; 
eight of the remaining nine infants had a positive culture of blood or CSF. There was no 
significant difference between the treatment groups. (Table 5) 
Discussion 
In this study more infants had Gram positive than Gram negative infections. When 
treated with either benzylpenicillin + gentamicin or ceftriaxone, the outcomes in the two 
treatment groups were similar. This finding resembles the results of a meta-analysis of studies 
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that used either of these two protocols.4  In a previous review of CSF results in our own hospital, 
Swann et al reported that more neonatal cultures were sensitive to ceftriaxone than to 
benzylpenicillin and gentamicin (99.1% vs 91.8%; p=0.006), especially the Gram-negative 
isolates (95.1% v 86.0%; p=0.012).21  A similar review of neonatal blood cultures done over that 
same period of time showed that 53% of the pathogens were Gram-positive and 47% Gram-
negative. The four most common pathogens were S. aureus, GBS, Salmonella Typhimurium, and 
E. coli.22  Klebsiella sp, Acinebacter sp and Enterobacter sp, all considered nosocomial 
infections, accounted for 7.3%, 3.1% and 4.6% of the Gram negative pathogens The results of 
our study differ because we included all cases of possible severe bacterial infection, as this 
reflects clinical practice; only 147 (45%) blood or CSF samples grew bacteria of which 62 (42%) 
were coagulase negative staphylococci that may, or may not, have been contaminants. Even if 
the coagulase negative staphylococci are excluded we had more Gram positive (n=36/45; 80%) 
than Gram negative (n= 9/45; 20%) infections. This is probably because there has been a decline 
in invasive non typhoidal salmonella infections in Malawi over the last decade 26 and we 
excluded nosocomial infections.  
More infants in the benzylpenicillin/gentamicin group developed jaundice than in the ceftriaxone 
group. Jaundice was caused mainly by the underlying infection; only seven of 24 (30%) infants 
commenced phototherapy after starting antibiotics. The overall hospital mortality was 42/348 
(12.1%) and 4.6% survived with sequelae. Hearing loss was related to the underlying infection 
and not to the treatment.  The outcome was worse in culture positive pSBI than in culture-
negative infants (p=0.017) and worse in infants who were HIV infected or exposed than 
unexposed (p= 0.008).  
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Forty one children died in hospital but after six months a further 11 had died. Sixteen children 
were identified in hospital as having sequelae but by six months 17 more children were found to 
have sequelae. It is clear that all infants with pSBI need follow up to ensure additional supportive 
care for those who need it as about half who will eventually have sequelae are likely to be missed 
at the time of hospital discharge. 
 
Conclusions: 
Ceftriaxone is safe in infants in our setting – in particular its use was not associated with a higher 
frequency of jaundice in this study – and hearing was not affected by gentamicin use. In this 
study, which did not include infants likely to have nosocomial infections, the outcome from pSBI 
was similar whether infants were treated with benzylpenicillin and gentamicin or with 
ceftriaxone. Infants with pSBI should be followed up for at least 6 months, as many may develop 
sequelae that were not detected on hospital discharge. 
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Characteristic Unit of measure Ceftriaxone   
N =170 
Penicillin/Gentamicin 
N=161 
Total * 
N = 331 
P 
value 
Sex:N (%) Female 82/167
(49%) 
75/157 (48%) 157/324
(48%) 
0.83
Known 
Birth weight   
Number (%) 123 (72) 132 (82) 255 (77) 0.05 
Admission 
weight Kgs 
Number known (%)   
Median [IQR] 
170 (100) 
3.2 [1.9, 4.5] 
160 (99) 
3.1 [1.9, 4.2] 
330 
(99.5) 
0.49 
Age groups:  
n (%) 
 
≤7 days                    
8days -30days            
≥ 30 days 
34 (20) 
93 (55) 
43 (25) 
43 (27) 
78 (48) 
40 (25) 
77 (23) 
171(52) 
83 (25) 
0.33 
Mode of 
delivery n(%) 
LSCSa/Instrumental 
SVD 
Unrecorded 
 16 (9) 
151(89) 
    3 (2) 
10  (6) 
150 (93) 
    1 (1) 
26 (8) 
301(91) 
  4 (1) 
0.31 
Parity: n (%) Single                     
Twins 
Unrecorded
152 (89) 
  16 (9.5) 
2 (0.5)
151 (94) 
    9 (5.5) 
1 (0.5)
303(92) 
25 (7.5) 
3 (0.5)
0.21 
Temperature: n
(%) 
<36.50 C
36.5- 37.50 C           
>37.50 C 
Unrecorded 
26 (15.5)
106 (62.5) 
36 (21.5) 
  2 (0.5) 
20 (12)
98 (61) 
41 (26) 
  2 (1) 
46 (14)
204(62) 
77 (23) 
  4 (1) 
0.56
Fever days:n 
(%) 
≤1 day                        
1 - 2 day                     
>2 days 
Unrecorded 
85 (50) 
40 (24) 
43 (25) 
  2 (1) 
78 (48) 
42 (26) 
40 (25) 
  1 (1) 
163(49) 
82 (25) 
83 (25) 
  3 (1) 
0.88 
Sucking : n (%) Yes                             
No 
Unrecorded 
116 (68) 
52 (31) 
  2 (1) 
124 (79.5) 
36 (22) 
  1 (0.5) 
240(72.5) 
88 (26.5) 
  3 (1) 
0.10 
Convulsions: n 
(%) 
Yes                             
No 
Unrecorded 
22 (13) 
147 (86.5) 
  1 (0.5) 
15 (9.5) 
145 (90) 
  1 (0.5) 
37 (11.5) 
292(88) 
2 (0.5) 
0.38 
Total bilirubinb  
n (%) 
<1mmol/l                   
>1 mmol/l 
Unrecorded 
158 (93.5) 
   9 (5.5) 
   3 (1) 
138 (86) 
 21 (13) 
 2 (1) 
296(90) 
30 (9) 
 4 (1) 
0.02 
Difficult 
breathing: n (%) 
No                              
Yes 
Unrecorded 
82 (48) 
85 (50) 
  3  (2) 
80 (49.5) 
80 (49.5) 
  1 (0.5) 
162(49.5) 
165(49.5) 
  4 (1) 
0.91 
Cough days:  
n (%) 
≤1 day                        
>1 day 
Unrecorded 
119 (70) 
50 (29.5) 
  1 (0.5) 
112 (69.5) 
48 (30) 
1 (0.5) 
231(70) 
98 (29) 
 2 (0.5) 
1 
Haemoglobin Number tested (%) 
Median g/dl{range} 
162 (95) 
12.5{3.6-39} 
148 (92) 
12.95{1.1 -22.8} 
310(94) 0.26 
Oxygen 
saturation % 
≤90%                    
>90% 
Unrecorded 
112 (66) 
49   (29) 
  9   (5) 
106 (66) 
48 (30) 
  7 (4) 
218(66) 
97 (29.5) 
16 (4.5) 
0.90 
Total blood 
WBC : n(%) 
≤5000 cm3                    
5 - ≤10,000 cm3       
10 –  ≤15,000 cm3 
>15,000cm3 
Unrecorded 
16 (9) 
49 (29) 
52 (31) 
44 (26) 
 9 (5) 
18 (11) 
38 (24) 
44 (27) 
47 (29) 
14 (9) 
34 (10.5) 
87 (26) 
96 (29) 
91 (27.5) 
23 (7) 
0.65 
Malaria Parasites 
on BFc or positive 
MRDTd  n(%) 
Negative                   
Not done 
155 (91) 
15 (9) 
144 (89) 
17 (11) 
299(90) 
 32 (10) 
0.71 
*excluded	17	cases	who	received	both	antibiotic	therapies;	a	=	lower		section	Caesarean	section;		b	measured transcutanously c	Blood	film;	dMalaria	rapid	diagnostic	test		Table	1	Baseline	characteristics	on	admission	
 
Table 1
	
 
 
 
 
 
 
 
Table 2. CSF and Blood culture findings in neonatal sepsis 
                              CSF culture results       Blood Culture results 
             Number(%)     Number(%)   
            Not done/missing         53 (15)               7   (2)        
      No growth*      254  (73)        220 (66)   
                     Group B streptococcus        15   (4)           16   (5)      
 Coagulase negative staphylococcus         8    (2)            63 (19)  
             Streptococcus pneumoniae**       8   (2)                   5   (1) 
                  Streptococcus pyogenes          2    (1)              0 
                    Staphylococcus aureus        0       11 (3) 
                   Group D streptococcus          0         1 (0.5) 
      Alpha haemolytic streptococcus        2   (1)         3 (1)     
                                  Gram negativex       6  (2)                          9 (2.5)      
                Total           348 (100)                 335 (100) 
*12 CSFs with no growth on culture had white cell counts (number of cells = 23-clumps in pus) 
suggestive of meningitis, 3 of these infants had positive blood cultures (1 each of Group B 
streptococcus, coagulase negative staphylococcus and alpha haemolytic streptococcus, **1 had Gram 
positive diplococci on Gram stain, but was culture negative) 
x The Gram negative bacteria were E. coli 3, Acinebacter baumanni 2, salmonella Typhimurium 1, 
Enterobacter cloacae 1, Acinebacter lwolfi 1.  
All diploccici, microcci, and bacilli were considered contaminants. Coagulase negative staphylococci 
and alpha haemolytic streptococci may have been contaminants but some of the infants from whom the 
samples were taken were very ill. 
 
 
 
Table 2
		
Table 3  Multivariate analyses of variables affecting outcome 
 
             Outcome             Multivariate 
Variable Number  
assessed 
Alive, no 
Sequelae 
N= 186 
Dead or 
Sequelae 
N= 91 
OR, 95% CI    P 
value 
 Gentamicin/Penicillin  134 96 (63) 38 (37)   
          Ceftriaxone 143 90 (72) 53 (28) 0.69 (0.34, 1.36) 0.28 
CSF culture -ve  200 136 (68) 64 (32)   
 CSF culture +ve  36 21 (58) 15 (42) 2.15 (0.89, 5.15) 0.08 
Blood culture -ve                   181 128 (71) 53 (29)   
Blood culture  +ve 93 55 (59) 38 (41) 2.15 (1.07, 4.38) 0.033 
Weight  Kg    >2.5 225 162 (72) 63 (28)   
                        <=2.5 51 24 (47) 27 (53) 2.46 (1.12, 5.42) 0.024 
HIV -ve 
HIV exposed  
195
56 
134 (69)
42 (75) 
61 (31)
14 (25) 1.15 (0.49,2.58) 
HIV+ve  9 3 (33) 6 (67) 4.30 (0.84,25.2) 0.22 
Convulsion none  248 175 (71) 73 (29)   
Convulsions  27 9 (33) 18 (67) 5.22 (1.82,16.7) 0.003 
Sucking 200 153 (77) 47 (24)   
Not sucking 74 30 (41) 44 (59) 2.61 (1.26, 5.44) 
 
0.010 
Oxygen saturation ≥90% 179 130 (73) 49 (27)   
Oxygen saturation < 90% 83 46 (55) 37 (45) 2.34 (1.12, 4.96) 0.025 
Cough≤ 1 day 195 126 (65) 69 (35)   
Cough > 1day 80 58 (73) 22 (28) 0.78 (0.49, 2.58) 0.53 
      OR	=odds	ratio;	CI	=	confidence	interval			
 
 
 
 
 
 
Table 3
		
Table	4  Transcutaneous	bilirubin	levels	at	admission	and	the	rise	in	bilirubin	levels	with	benzylpenicillin	+gentamicin	and	ceftriaxone 
	
Serum	
bilirubin	
levels	μmol/L	
Benzylpenicilln/	
Gentamicin	
N	
Benzylpenicillin/	
Gentamcin	
requiring	
phototherapy	
N(%)	
Ceftriaxone	
N	
Ceftriaxone	
requiring	
Phototherapy	
N(%)	<5	 100	 0	 135	 														0	5	-	<10	 17	 0	 14	 														1	10	-	<15	 18	 2	 14	 														1	15	-	<20	 11	 6	 5	 														3	>20	 14	 11	 2	 														2	
Total	 130	 19	(15%)	 135	 						7	(6%)					p=0.03	Not	done*	 18		 0	 18		 0	Received	both	antibiotic	regimens*	 17	 1	 	 	
Rise	in	serum	bilirubin	level	(μmol/L)	during	admission			 	<10	 26	 0	 24	 0	>10	 0	 0	 1	 0	
Total	 26	 0	 25	 0	
																	*	36	had	no	bilirubin	measured	or	it	was	not	measured	immediately	on	admission																			 			
Table 4
Table 5 
Hearing test results (and neurological deficits) in survivors in the benzylpenicillin/gentamicin and ceftriaxone treatment arms at 6 
months follow up 
 
 
Hearing status(neuro deficits) N     Benzylpenicillin/gentamicin           Ceftriaxone  Received both antibiotics 
Bilateral Hearing Loss             4 ( 4 with global delay)   2(1 CP 1 blind)     0  
Unilateral Hearing Loss                      5 (1 with global delay)   5       0 
Total with hearing deificts                 9     5       0 
 
Normal Hearing                              50 (4 global delay, 1 hemiplegia 52 (4 hydrocephalus, 2 blind    8 (1 global delay) 
           (1 fine motor deficit)       (5 global delay, 1 hemiplegia)  
TOTAL  TESTED                        68  (11 with neuro deficits)        64 (14 with neuro deficits)      8 (1 with neuro deficits)  
 
Children not tested or                     56              61       4 
Inconclusive result 
TOTAL  survivors at 6 months     124             125     12     
     
 	
 
 
 
 
 
 
 
 
 
 
Table  5
 
Table 7 ORIGINAL  
Hearing test results and neurological deficits in treatment arms benzylpenicillin/gentamicin and ceftriaxone at 6 months follow up 
 
Hearing status (neuro deficit)  N         benzylpenicillin/gentamicin Ceftriaxone  received both antibiotics 
Bilateral Hearing Loss 13 8(5 global delay) 4 (1 CP, 1 blind, 1 seizures) 1 (1 global delay)
Unilateral Hearing Loss              8                 4(1 global delay)  4    0 
Inconclusive test results              4                 2    2    0 
Normal Hearing                       191               90   (4 global delay,)            96 (4 hydrocephalus, 2 blind) 5 
           (1 hemiplegia 1 fine motor)     (5 global delay, 1 hemiplegia) 
TOTAL                                   216            104 (12 neuro deficits)         106 (15 neuro deficits)           6 (1 neuro deficit)  
Not tested                                135     62    67              6 
neuro = neurological; CP = cerebral palsy 	
		
Pencillin/Gentamicin	N	=	161	Deaths	18	Withdrew	3	
Alive													=	124:	77%					[Sequelae			=	14/124:11.3%]	Deaths									=	22:13.7%	LTFU/abs			=	15	:	9.3%	
Alive											=	12	:70.6%	[Sequelae						=		1	(8.3%]	Deaths							=	4:23.5%	LTFU/abs	=	1;5.9%		
Alive												=	125:	73.5%							[Sequelae		=	18/125:14.4%]	Deaths									=	28:16.5	%	LTFU	etc					=	17:10	%	
				N	=	3							2	not	requiring	antibiotics							1	withdrew	consent								
N=	351	enrolled	
Ceftriaxone		N	=170	Deaths	19	Absconded	1	Pen/Gent	+	Ceftriaxone*	N=17	Deaths	4	Absconded	1	
*	ceftriaxone	was	added	during	treatment	:	LFTU	=	Lost	to	follow	up:	abs	=	absconded		
N	=	348	
Figure	1.	Study	enrollment	and	outcome	
10	LTFU	4	deaths	 I	LTFU	 2	notes	missing	12	deaths	
Outcome	at	six	months	post	discharge	
Figure 1
SDC Table 1 
LEVELS OF BILIRUBIN AT WHICH TO START PHOTOTHERAPY IN TERM INFANTS 
 	
SDC 1 table Click here to download Supplemental Digital Content
(Including Separate Legend) SDC table 1.docx
SDC Table 2 
 LEVELS OF BILIRUBIN AT WHICH TO START PHOTOTHERAPY IN PREMATURE INFANTS 
Gestational 
age 
Day 1 Day2 Day 3 Day 4 Day 5 Day 6 Day 7
24 wks 3.5 mg/dl 5.8 7.6 7.6 7.6 7.6 7.6 
 60 umol/L 100 130 130 130 130 130 
26 wks 5.3 mg/dl 7.6 9 9 9 9 9 
 90 umol/L 130 160 160 160 160 160 
28wks 6.4 mg/dl 8.8 10.5 10.5 10.5 10.5 10.5 
 110 umol/L 150 180 180 180 180 180 
30wks 8.2 mg/dl 10.5 12 12 12 12 12 
 140 umol/L 180 210 21 210 210 210 
32wks 9.3 mg/dl 11.7 13 13 13 13 13 
 160 umol/L 200 230 230 230 230 230 
34 wks 9.8 mg/dl 12.2 14 14 14 14 14 
 170 umol/L 210 240 240 240 240 240 
36 wks 11 mg/dl 13.4 15 15 15 15 15 
 190umol/L 230 260 260 260 260 260 	
SDC 2 table Click here to download Supplemental Digital Content
(Including Separate Legend) SDC Table 2.docx
SDC Table 3 CSF and blood culture findings and outcomes in infants with 
possible severe bacterial infection.                       
 3a CSF culture and overall outcome at 6 months post discharge 
Culture 
 Outcome at 6 months post discharge   
alive dead sequelae LTFU* Total  p value 
            No growth* 134 30 37 14 215 No growth 
v 
combined
positive 
cultures  
P = 0.003 
(Chi-
squared 
test) 
       coagulase negative 
staphylococcus 
    4   3   0   0     7 
  Group B streptococcus     6   3   3   0   12 
             Not done   16   10   1   4   31 
              Gram negatives     1    1   1   3     6 
Strep pneumoniae a     3    3   0   0     6 
Streptococcus pyogenes     2    0   0   0     2 
                Total 166 50 42 21 279   
aStreptococcus pneumonia 
Of 12 no growth but cell counts suggestive of Bacterial Meningitis, 4 were Alive, 1 Died, 1 had 
sequelae and 1 was lost to follow up   *LFTU = lost to follow up/absconded 
3b Blood culture and overall outcome at 6 months post discharge 
Culture 
 Outcome at 6 months post discharge   
alive dead sequelae LTFU* Total  p value 
            No growth 124 28 26 9 187 
No growth 
v 
combined 
positive 
cultures 
P= 0.04 
      Coagulase neg stapha   30  7   8 7   52 
  Group B streptococcus     5   5   1 1   12 
             Not done     2   0   0 0     2 
              Gram negatives     3   3   1 1     8 
Strep  pneumoniaeb     3   1   1 0     5 
A haem streptococcus 	     2   0   2 0     4 
Group D streptococcus     1   0   0 0     1 
Staphylococcus aureus     3   5   0 1     9 
                Total 172 49 39 19 279 
*LFTU = lost to follow up a coagulase negative staphylococci; b Streptococcus pneumonia; c alpha 
haemolytic streptococcus. 	
SDC 3 table Click here to download Supplemental Digital Content
(Including Separate Legend) SDC Table 3 CSF and blood
